{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:25:44Z","timestamp":1791077144425,"version":"4.1.0"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,6,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> The rare association between breast cancer and pregnancy means that few oncologists gain an expertise in this area. In particular, there are few published data concerning the use of chemotherapy for breast cancer during pregnancy. In this retrospective case series, we describe the experiences of five hospitals in London, United Kingdom, and how they manage this condition. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Retrospective searches were performed at five London hospitals in order to identify women who received chemotherapy for breast cancer while pregnant. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Twenty-eight women were identified who had received chemotherapy for breast cancer during pregnancy. Twenty-four women received adjuvant or neoadjuvant chemotherapy for early breast cancer, and four women received palliative chemotherapy for metastatic disease. A total of 116 cycles of chemotherapy were administered during pregnancy. Sixteen women were treated with anthracycline-based chemotherapy and 12 received cyclophosphamide, methotrexate, and fluorouracil. All but one of the women were treated after the first trimester. One spontaneous abortion occurred in the woman treated during her first trimester; otherwise, there were no serious adverse consequences for the mothers or neonates. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> These data provide evidence that in terms of peripartum complications and immediate fetal outcome, chemotherapy can be safely administered to women during the second and third trimesters of pregnancy. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.03.038","type":"journal-article","created":{"date-parts":[[2005,6,17]],"date-time":"2005-06-17T01:27:40Z","timestamp":1118971660000},"page":"4192-4197","source":"Crossref","is-referenced-by-count":227,"title":["Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals"],"prefix":"10.1200","volume":"23","author":[{"given":"Alistair E.","family":"Ring","sequence":"first","affiliation":[{"name":"From the Breast Unit, Royal Marsden Hospital; Royal Free Hospital; Guy's, King\u2019s, and St Thomas' Cancer Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Breast Unit, Royal Marsden Hospital; Royal Free Hospital; Guy's, King\u2019s, and St Thomas' Cancer Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Jones","sequence":"additional","affiliation":[{"name":"From the Breast Unit, Royal Marsden Hospital; Royal Free Hospital; Guy's, King\u2019s, and St Thomas' Cancer Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Shannon","sequence":"additional","affiliation":[{"name":"From the Breast Unit, Royal Marsden Hospital; Royal Free Hospital; Guy's, King\u2019s, and St Thomas' Cancer Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Galani","sequence":"additional","affiliation":[{"name":"From the Breast Unit, Royal Marsden Hospital; Royal Free Hospital; Guy's, King\u2019s, and St Thomas' Cancer Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Ellis","sequence":"additional","affiliation":[{"name":"From the Breast Unit, Royal Marsden Hospital; Royal Free Hospital; Guy's, King\u2019s, and St Thomas' Cancer Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S0147-0272(83)80006-3"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.79.12.1675"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.24"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.026"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Lubchenco LO, Hansman C, Dressler M, et al: Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics 32:793,1963-800,","DOI":"10.1542\/peds.32.5.793"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2266::AID-CNCR14>3.0.CO;2-7"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.855"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11614"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1992.tb02737.x"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(92)91334-7"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<720::AID-IJC3>3.0.CO;2-U"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.088"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1078\/0344-0338-00347"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1968.tb02083.x"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Gililland J, Weinstein L: The effects of cancer chemotherapeutic agents on the developing fetus. Obstet Gynecol Surv 38:6,1983-13,","DOI":"10.1007\/978-1-4613-3912-0_2"},{"key":"R18","unstructured":"Doll DC, Ringenberg QS, Yarbro JW: Antineoplastic agents and pregnancy. Semin Oncol 16:337,1989-346,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840901)54:5<800::AID-CNCR2820540505>3.0.CO;2-R"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400150093017"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00356-5"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6439"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2354.2000.00231.x"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6341"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/0301-2115(96)02444-X"},{"key":"R26","unstructured":"Stoll BJ, Kliegman RM: The high risk infant, in, Behrman RE, Kliegman RM, Jenson HB (eds): Nelson Textbook of Pediatrics, 16th Edition . Philadelphia, PA, WB Saunders Company, pp 474,2000-485"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Murray NA, Acolet D, Deane M, et al: Fetal marrow suppression after maternal chemotherapy for leukaemia. Arch Dis Child Fetal Neonatal Ed 17:F209,1994-F210,  (suppl)","DOI":"10.1136\/fn.71.3.F209"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.7.1098"},{"key":"R29","unstructured":"Partridge AH, Garber JE: Long-term outcomes of children exposed to antineoplastic agents in utero. Semin Oncol 27:712,2000-726,"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2001.n.023"},{"key":"R31","unstructured":"Gaillard B, Leng JJ, Grellet J, et al: Transplacental passage of epirubicin [in French]. J Gynecol Obstet Biol Reprod (Paris) 24:63,1995-68,"},{"key":"R32","unstructured":"Karp GI, von Oeyen P, Valone F, et al: Doxorubicin in pregnancy: Possible transplacental passage. Cancer Treat Rep 67:773,1983-777,"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880201)61:3<435::AID-CNCR2820610305>3.0.CO;2-F"},{"key":"R34","unstructured":"Garber JE: Long-term follow-up of children exposed in utero to antineoplastic agents. Semin Oncol 16:437,1989-444,"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0705.2001.00373.x"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.03.038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:06:58Z","timestamp":1653512818000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.03.038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,20]]},"references-count":34,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2005,6,20]]}},"alternative-id":["10.1200\/JCO.2005.03.038"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.03.038","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,20]]}}}